- BrainStorm Cell Therapeutics, headquartered in American Fork, Utah, specializes in developing adult stem cell therapeutics for neurodegenerative diseases, positioning itself as a leader in this niche market.
- In early 2026, the company secured $2.0 million in strategic financing and received FDA clearance for a Phase 3b study of its NurOwn platform, marking significant progress in its clinical development.
- BrainStorm has established a network of leading clinical sites for its therapies and is actively engaged with regulators to advance its product offerings.
- The ideal buyer for BrainStorm's solutions includes healthcare providers and institutions focused on treating neurodegenerative diseases, addressing critical patient needs for innovative therapies in this challenging medical field.
BrainStorm's workforce is organized into 15 distinct departments, with Operations leading at 26 employees, followed closely by Sales with 22 and Engineering at 19. This distribution indicates a strong emphasis on operational efficiency and sales capabilities, essential for driving growth in the software development sector. The balanced presence of departments such as Executive and Information Technology, with 18 and 14 employees respectively, further supports the company's strategic objectives.
The company operates across 20 locations, with a significant concentration in American Fork, UT, housing 39 employees, and Vineyard, UT, with 20. The presence of only a few employees in major cities like New York and Miami suggests a strategic focus on regional operations rather than a widespread urban footprint. Additionally, the 'Other' category accounts for 106 employees, indicating a distributed workforce that may be working remotely or in less centralized locations.
